🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

164 results for “Ars” Clear

  1. Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28

    SINOVAC BIOTECH LTD

    COVID-19

    phase 2 mab completed

    2 trials

  2. Upamostat

    RedHill Biopharma

    SARS-CoV-2

    phase 2 small molecule completed

    1 trial

  3. VLA2001

    United Therapeutics Europe Ltd

    SARS-CoV-2 Virus Infection

    phase 2 mab completed

    1 trial

  4. Vehicle of TP-03

    Tarsus Pharmaceuticals

    Meibomian Gland Dysfunction

    phase 2 small molecule active

    1 trial

  5. ZIO-101 (Darinaparsin)

    Alaunos Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  6. lotilaner

    Tarsus Pharmaceuticals

    Ocular Rosacea

    phase 2 small molecule active

    1 trial

  7. low-dose Recombinant SARS-CoV-2 Vaccine (CHO cell)

    China SXT Pharmaceuticals

    COVID-19

    phase 2 mab completed

    1 trial

  8. A Phase I, Open-label, Randomized, Active-Controlled, to Evaluate the Safety and Immunogenicity of the DuoChol Oral Cholera Vaccine in 18 to 45 years old Healthy Participants in Sweden.

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Prevention of Cholera disease

    phase 1 other active

    1 trial

  9. A Study to Learn About if the Study Medicine Called Ibuzatrelvir changes how the body process the other Medicine Dabigatran Etexilate in healthy adults

    Pfizer Ireland Pharmaceuticals Unlimited Company

    severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

    phase 1 other active

    1 trial

  10. A randomized, Phase 1b, single-center, observer-blind, active-controlled study to evaluate the safety, immunogenicity, and immunological mechanisms of one single administration of TETRALITE influenza vaccine at two dose levels of LiteVax Adjuvant, in healthy participants aged 60 years and older and in healthy participants aged 18 to 50 years.

    Teva Pharma GmbH

    Influenza

    phase 1 other active

    1 trial

  11. A randomized, Phase I, single-center, observer-blind, active-controlled study to evaluate the safety, tolerability and immunogenicity of one single administration of PCV-LITE, a novel adjuvanted pneumococcal conjugate vaccine at one dose level of LiteVax Adjuvant, in healthy participants aged 18-50 years.

    Teva Pharma GmbH

    Pneumococcal infection

    phase 1 other active

    1 trial

  12. A randomized, open-label, single dose, 2-way crossover bioequivalence study comparing apixaban 5 mg hard capsules (PG412 [Celon Pharma]) vs apixaban 5 mg film-coated tablets (Eliquis [Bristol-Myers Squibb]) under fasting conditions in healthy volunteers

    Pharma Mar S.A.

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  13. A study comparing the new drug PG413 produced by Celon Pharma SA with the drug Eliquis available on the market in healthy volunteers.

    Pharma Mar S.A.

    Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.

    phase 1 other active

    1 trial

  14. A study to investigate immune challenge induced skin reactions with SAR445399, canakinumab and spesolimab compared with placebo, in healthy participants aged 18 to 55 years

    Sanofi Pharma Bristol-Myers Squibb

    Immuun system diseases

    phase 1 other active

    1 trial

  15. A study to investigate the pharmacokinetics of a combined oral contraceptive when given alone and in combination with GSK3036656 in female participants of non-childbearing potential aged 18 to 65 years of age

    GlaxoSmithKline Biologicals S.A.

    Tuberculosis

    phase 1 other active

    1 trial

  16. A study to investigate the safety, tolerability, pharmacokinetics, immunogenicity and pharmacodynamics of a single subcutaneous dose of GSK4771261 in healthy participants aged 25 to 55 years of age inclusive

    GlaxoSmithKline Biologicals S.A.

    Autosomal Dominant Polycystic Kidney Disease

    phase 1 other active

    1 trial

  17. A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants

    Bayer AG

    Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.

    phase 1 other active

    1 trial

  18. A study to learn about the taste of Vericiguat given in liquid form in healthy male participants aged 18 to 45 years

    Bayer AG

    Heart failure in children

    phase 1 other active

    1 trial

  19. ARS-1 with URTI

    Ars Pharmaceuticals Irl Limited

    Upper Respiratory Tract Infection

    phase 1 small molecule completed

    1 trial

  20. An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fasting condition.

    Pharma Mar S.A.

    ulcerative colitis

    phase 1 other active

    1 trial

  21. An open label, balanced, randomized, two-treatment, four-period, two-sequence, single-dose, crossover fully replicate bioequivalence study comparing Mesalamine delayed release capsules 400 mg manufactured by Sun Pharmaceutical Industries Limited, India with Mesalamine Delayed-Release Capsules 400 mg, manufactured for Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, in healthy, adult, human subjects under fed condition.

    Pharma Mar S.A.

    ulcerative colitis

    phase 1 other active

    1 trial

  22. Arsenic trioxide

    Teva Pharma GmbH

    Chronic Myelogenous Leukemia

    phase 1 small molecule terminated

    1 trial

  23. COVID-HIG

    United Therapeutics Europe Ltd

    SARS-CoV-2 Infection

    phase 1 mab completed

    1 trial

  24. Dociparstat sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources